Please find the attached Disclosure
Awaiting price reaction for this filing.
Cresanto Global Ltd (formerly Raymed Labs Limited), a small-cap BSE-listed company (Scrip Code: 531207), filed two related letters to BSE dated 22 May 2025. The first submits its half-yearly Related Party Transactions disclosure for Q4 and the half year ended 31 March 2025 under Regulation 23(9) of SEBI's Listing Regulations. The second letter clarifies that the company is actually exempt from this requirement because its paid-up equity share capital is below Rs. 10 crore and net worth is below Rs. 25 crore, making it fall under the exemption under Regulation 15(2) of SEBI (LODR) Regulations, 2015. The filings are signed by Managing Director Prashant Nathmal Bajaj (DIN: 06634046).
This is a routine procedural filing and does not indicate any material event. For retail investors, the key takeaway is that Cresanto Global is a very small company (paid-up capital under Rs. 10 crore), which is why it qualifies for reduced compliance requirements. No new financial information or transaction details are disclosed that would affect the stock price.